Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Generation of infectious HCV pseudo typed particles and its utilization for studying the role of CD81 & SRBI receptors in HCV infection.

Rafique S, Idrees M, Ali A, Sahibzada KI, Iqbal M.

Mol Biol Rep. 2014 Jun;41(6):3813-9. doi: 10.1007/s11033-014-3247-x. Epub 2014 Feb 19.

PMID:
24549717
2.

Inhibition of HCV 3a genotype entry through host CD81 and HCV E2 antibodies.

Ashfaq UA, Qasim M, Yousaf MZ, Awan MT, Jahan S.

J Transl Med. 2011 Nov 10;9:194. doi: 10.1186/1479-5876-9-194.

3.

Studies on the role of neutralizing antibodies against envelope genes in resolving HCV pseudo-particles infection.

Rafique S, Idrees M, Ali A, Iqbal M.

Mol Biol Rep. 2014 Jun;41(6):3945-50. doi: 10.1007/s11033-014-3262-y. Epub 2014 Feb 25.

PMID:
24566682
4.

[Development of infectious pseudo-particle harboring three subtypes hepatitis C virus glycoproteins and their application in neutralization assays].

Zhang K, Tan WJ, Deng Y, Li J, Wu XB, Ruan L.

Bing Du Xue Bao. 2008 Jul;24(4):287-94. Chinese.

PMID:
18780632
5.

Cell entry of hepatitis C virus requires a set of co-receptors that include the CD81 tetraspanin and the SR-B1 scavenger receptor.

Bartosch B, Vitelli A, Granier C, Goujon C, Dubuisson J, Pascale S, Scarselli E, Cortese R, Nicosia A, Cosset FL.

J Biol Chem. 2003 Oct 24;278(43):41624-30. Epub 2003 Aug 11.

6.
7.

Characterization of host-range and cell entry properties of the major genotypes and subtypes of hepatitis C virus.

Lavillette D, Tarr AW, Voisset C, Donot P, Bartosch B, Bain C, Patel AH, Dubuisson J, Ball JK, Cosset FL.

Hepatology. 2005 Feb;41(2):265-74.

PMID:
15660396
8.

Incorporation of primary patient-derived glycoproteins into authentic infectious hepatitis C virus particles.

Doerrbecker J, Friesland M, Riebesehl N, Ginkel C, Behrendt P, Brown RJ, Ciesek S, Wedemeyer H, Sarrazin C, Kaderali L, Pietschmann T, Steinmann E.

Hepatology. 2014 Aug;60(2):508-20. doi: 10.1002/hep.27190. Epub 2014 Jun 24.

PMID:
24771613
9.

Expression of human factors CD81, claudin-1, scavenger receptor, and occludin in mouse hepatocytes does not confer susceptibility to HCV entry.

Hikosaka K, Noritake H, Kimura W, Sultana N, Sharkar MT, Tagawa Y, Uezato T, Kobayashi Y, Wakita T, Miura N.

Biomed Res. 2011 Apr;32(2):143-50.

10.

Analysis of a conserved RGE/RGD motif in HCV E2 in mediating entry.

Rothwangl KB, Rong L.

Virol J. 2009 Jan 26;6:12. doi: 10.1186/1743-422X-6-12.

11.

Dissecting the role of putative CD81 binding regions of E2 in mediating HCV entry: putative CD81 binding region 1 is not involved in CD81 binding.

Rothwangl KB, Manicassamy B, Uprichard SL, Rong L.

Virol J. 2008 Mar 20;5:46. doi: 10.1186/1743-422X-5-46.

12.

Mutations in hepatitis C virus E2 located outside the CD81 binding sites lead to escape from broadly neutralizing antibodies but compromise virus infectivity.

Keck ZY, Li SH, Xia J, von Hahn T, Balfe P, McKeating JA, Witteveldt J, Patel AH, Alter H, Rice CM, Foung SK.

J Virol. 2009 Jun;83(12):6149-60. doi: 10.1128/JVI.00248-09. Epub 2009 Mar 25.

13.

Two conserved histidines (His490 and His621) on the E2 glycoprotein of hepatitis C virus are critical for CD81-mediated cell entry.

Qin ZL, Ju HP, Gao TT, Wang WB, Ren H, Zhao P, Qi ZT.

J Gen Virol. 2015 Jun;96(Pt 6):1389-99. doi: 10.1099/vir.0.000091. Epub 2015 Feb 20.

PMID:
25701820
14.

CLEC4M-positive and CD81-negative Huh7 cells are not susceptible to JFH-1 HCVcc infection but mediate transinfection.

Ishibashi M, Morita N, Nomura-Kawaguchi C, Shimizu Y, Wakita T, Esumi M.

Arch Virol. 2014 Nov;159(11):2949-55. doi: 10.1007/s00705-014-2150-z. Epub 2014 Jun 26.

PMID:
24965233
15.

Diverse hepatitis C virus glycoproteins mediate viral infection in a CD81-dependent manner.

McKeating JA, Zhang LQ, Logvinoff C, Flint M, Zhang J, Yu J, Butera D, Ho DD, Dustin LB, Rice CM, Balfe P.

J Virol. 2004 Aug;78(16):8496-505.

16.

Identification of conserved residues in hepatitis C virus envelope glycoprotein E2 that modulate virus dependence on CD81 and SRB1 entry factors.

Lavie M, Sarrazin S, Montserret R, Descamps V, Baumert TF, Duverlie G, Séron K, Penin F, Dubuisson J.

J Virol. 2014 Sep;88(18):10584-97. doi: 10.1128/JVI.01402-14. Epub 2014 Jul 2.

17.

Critical interaction between E1 and E2 glycoproteins determines binding and fusion properties of hepatitis C virus during cell entry.

Douam F, Dao Thi VL, Maurin G, Fresquet J, Mompelat D, Zeisel MB, Baumert TF, Cosset FL, Lavillette D.

Hepatology. 2014 Mar;59(3):776-88. doi: 10.1002/hep.26733. Epub 2014 Jan 28.

PMID:
24038151
18.

A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.

Zuiani A, Chen K, Schwarz MC, White JP, Luca VC, Fremont DH, Wang D, Evans MJ, Diamond MS.

J Virol. 2016 Nov 14;90(23):10499-10512. Print 2016 Dec 1.

19.

A view of the E2-CD81 interface at the binding site of a neutralizing antibody against hepatitis C virus.

Harman C, Zhong L, Ma L, Liu P, Deng L, Zhao Z, Yan H, Struble E, Virata-Theimer ML, Zhang P.

J Virol. 2015 Jan;89(1):492-501. doi: 10.1128/JVI.01661-14. Epub 2014 Oct 22.

20.

Adaptation of hepatitis C virus to mouse CD81 permits infection of mouse cells in the absence of human entry factors.

Bitzegeio J, Bankwitz D, Hueging K, Haid S, Brohm C, Zeisel MB, Herrmann E, Iken M, Ott M, Baumert TF, Pietschmann T.

PLoS Pathog. 2010 Jul 1;6:e1000978. doi: 10.1371/journal.ppat.1000978.

Supplemental Content

Support Center